Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance therapy after remission in moderate-to-severe erosive esophagitis: is prolonged PPI treatment necessary?
MOH_2025-06-17_014149Phase 4Not yet recruiting
- Sponsor
- ד"ר פביאנה בנימינוב
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esomeprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (2 arms), sponsored by ד"ר פביאנה בנימינוב. Primary endpoint: Recurrent esophagitis on repeat endoscopy. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
esomeprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on MOH_2025-06-17_014149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-17_014149.